probenecid has been researched along with Cytomegalovirus Retinitis in 7 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Cytomegalovirus Retinitis: Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Average key pharmacokinetic parameters (Cmax, tmax, lambda z, AUC0-infinity, Vss, CL, CLR, fe, ER) for RDP differed by less than 17% from SDP and were consistent with previously reported SDP data." | 6.71 | Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. ( Duncan, BA; Ingrosso, A; Mucci, M; Nickens, DJ; Rodríguez, CA; Wolf, DL, 2003) |
| "The authors characterize and analyze the incidence of a previously reported mild anterior nongranulomatous uveitis associated with intravitreal injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC), also termed cidofovir (Vistide, Gilead Sciences, Foster City, CA)." | 5.08 | Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. ( Arevalo, JF; Chavez-de la Paz, E; De Clercq, E; Freeman, WR; Kirsch, LS; Munguia, D; Rahhal, FM, 1997) |
| " Average key pharmacokinetic parameters (Cmax, tmax, lambda z, AUC0-infinity, Vss, CL, CLR, fe, ER) for RDP differed by less than 17% from SDP and were consistent with previously reported SDP data." | 2.71 | Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. ( Duncan, BA; Ingrosso, A; Mucci, M; Nickens, DJ; Rodríguez, CA; Wolf, DL, 2003) |
| " Dose-dependent asymptomatic proteinuria (39%) and serum creatinine elevation (24%) were the most common adverse events thought to be related to cidofovir." | 2.69 | Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. ( Hardy, WD; Holland, GN; Ives, DV; Jaffe, HS; Johnson, M; Kemper, CA; Kramer, F; Kuppermann, BD; Lalezari, JP; Lewis, RA; McKinley, GF; Nelson, R; Northfelt, DW; Ruby, AE; Simon, GL; Stagg, RJ; Weinberg, DV; Wolitz, RA; Youle, M, 1998) |
| "Eligible patients with acquired immune deficiency syndrome had active CMV retinitis in at least one eye and no evidence of extraocular CMV disease." | 2.68 | Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. ( Arevalo, JF; Chavez de la Paz, E; de Clercq, E; Freeman, WR; Kirsch, LS; Munguia, D, 1995) |
| " In addition, four treatment modifications were indicated to reduce the incidence of cidofovir-related nephrotoxicity: (a) dose reduction or interruption for changes in renal function; (b) concomitant administration of probenecid; (c) administration of 1 L of normal saline 1 h before infusion of cidofovir; and (d) extension of the dosing interval." | 2.40 | Cidofovir: a new therapy for cytomegalovirus retinitis. ( Lalezari, JP, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wolf, DL | 1 |
| Rodríguez, CA | 1 |
| Mucci, M | 1 |
| Ingrosso, A | 1 |
| Duncan, BA | 1 |
| Nickens, DJ | 1 |
| Kirsch, LS | 2 |
| Arevalo, JF | 2 |
| Chavez de la Paz, E | 1 |
| Munguia, D | 2 |
| de Clercq, E | 2 |
| Freeman, WR | 2 |
| Lalezari, JP | 2 |
| Chavez-de la Paz, E | 1 |
| Rahhal, FM | 1 |
| Holland, GN | 1 |
| Kramer, F | 1 |
| McKinley, GF | 1 |
| Kemper, CA | 1 |
| Ives, DV | 1 |
| Nelson, R | 1 |
| Hardy, WD | 1 |
| Kuppermann, BD | 1 |
| Northfelt, DW | 1 |
| Youle, M | 1 |
| Johnson, M | 1 |
| Lewis, RA | 1 |
| Weinberg, DV | 1 |
| Simon, GL | 1 |
| Wolitz, RA | 1 |
| Ruby, AE | 1 |
| Stagg, RJ | 1 |
| Jaffe, HS | 1 |
| Bowers, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)[NCT00000142] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 1994-04-30 | Completed | ||
| HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol[NCT00000799] | 100 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000142)
Timeframe: All patients enrolled will be followed until a common study closing date
| Intervention | participants (Number) | ||
|---|---|---|---|
| mortality | progression | va loss of 15 letters | |
| Cidofovir (High Dose) | 3 | 5 | 2 |
| Cidofovir (Low Dose) | 7 | 17 | 6 |
| Treatment Deferral | 6 | 20 | 4 |
1 review available for probenecid and Cytomegalovirus Retinitis
| Article | Year |
|---|---|
Cidofovir: a new therapy for cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Animals; Antiviral Agents; Cidofovir; Clinical Trials, Phase | 1997 |
5 trials available for probenecid and Cytomegalovirus Retinitis
1 other study available for probenecid and Cytomegalovirus Retinitis
| Article | Year |
|---|---|
Cidofovir.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytos | 1998 |